about
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpuraThrombotic microangiopathy with targeted cancer agentsInflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cellsEssential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis.Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation.Thrombomodulin mutations in atypical hemolytic-uremic syndrome.A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infectionAn autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF[Thrombotic-thrombocytopenic purpura].The role of endothelial cell injury in thrombotic microangiopathy.Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy.[Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpuraHematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy.Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura.Common variable immunodeficiency complicated with hemolytic uremic syndrome[ADAMTS13, von Willebrand factor specific cleaving protease].Seasonal association of thrombotic thrombocytopenic purpura.Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies.Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.Two novel heterozygote missense mutations of the ADAMTS13 gene in a child with recurrent thrombotic thrombocytopenic purpuraClinical causes and treatment of the thrombotic storm.Thrombotic microangiopathy in sickle cell disease crisis.Successful treatment of thrombotic thrombocytopenic purpura associated with mitral valve replacement.Secondary, profound, sensorineural hearing loss after recovery from haemolytic uraemic syndrome due to enterohaemorrhagic Escherichia coli, and subsequent cochlear implantation, in two Japanese children.AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpuraCurrent evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene.Role for platelet glycoprotein Ib-IX and effects of its inhibition in endotoxemia-induced thrombosis, thrombocytopenia, and mortality.Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkersAcquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: a case report.Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review.Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.Review: Complement and its regulatory proteins in kidney diseases.Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress.
P2860
Q24620546-6882F0A0-08E4-4A1D-86F9-C2216BE0E3DEQ24635904-6F36A350-0011-4D80-AAC1-ED4154F34190Q28564426-1A9089DB-7BEB-4F05-A655-3F85095DD5AAQ30504401-BD26EC7B-91C1-4B64-B6FC-A483882F33BBQ30577627-97E4535D-A723-47DE-94BF-DDB3A8B6BB64Q33382570-71260B43-456C-4776-A9C7-12F4B4A5D066Q33385474-4A6FA90B-5906-41D9-9F2F-5343375A87B8Q33386423-95A18A15-408B-4BFE-AB89-FC3EB32C6B83Q33387616-654E96E5-3349-4E1F-AF9C-F2B9B3115373Q33391233-CD3559C2-3DD6-4C54-92B0-2C0AB1A0BA14Q33391882-58597251-E5E7-48A2-8829-1A9B69A2E389Q33392316-854D5DB5-85C2-4182-B7F4-9EA523B016E0Q33393404-2692DBA9-198C-4A5F-8F25-D443B1DB82E9Q33393728-692C9092-CFD1-4D99-8C1C-525B3D3981F0Q33394765-EABF5BE4-0600-43CA-9331-6FB12DEEE0DAQ33395145-5C4FD15A-D335-4416-BF0E-A559E05ECBA9Q33398023-AC124D26-1D51-4DAA-8FEE-1EAF9E24A1BAQ33398887-7A4CA863-EA89-431A-A7DC-6282E37CEC78Q33399175-36374C59-7C9D-4796-84DD-53EEC46E43B0Q33399396-098535F9-4918-4A1B-81F5-9FEDDF271F25Q33401314-CA31DDEC-A15D-4E86-9AF8-AF54CFBB4E8AQ33402784-2AA86291-914C-443C-A7BA-23F5BF15301CQ33403769-0FEC56C4-7040-4FCA-9014-F0AA6140E499Q33404707-CE0786B4-3004-4F73-BCC5-BA709401FF9FQ33404745-83E140E9-C1F0-4BA8-B80F-F2EB4480B73BQ33405144-3FC4FE3C-9ACD-4AEC-9A19-CC74A575F4EDQ33405856-A67051C9-D3A9-4FC6-AEB4-A563368FB97BQ33406565-340658A1-F79D-42E6-8C7E-3231CAB1A6D5Q33409030-4E49BB77-FFB5-4451-814B-7E61603462AFQ33410318-5C6E8E42-6AA7-4333-B290-9A031CF44F38Q33410457-C00C00C0-C9C5-4A97-96A8-764265BBB668Q33415397-AEDA4991-FD57-4D97-90E9-B96CF8EED299Q33415463-A7E1B0C1-E358-4613-A5A5-63EDCCA6CDB8Q33423118-C8C0A758-E76C-4633-A972-08A239A69B58Q33430254-78FDD873-6A4A-41D4-B0D0-50C9859CB9B7Q33434516-9123AB57-5624-425E-A5AA-C6DA58A63760Q33443111-245FAD80-E851-49E4-AD35-18D418AAFC19Q33647738-1438E2A6-189D-4C12-80BB-41989185E0BCQ33747303-2A38B72E-02B8-472E-8671-947CDCBE96FEQ34121211-AB71A20F-C1F9-481A-B8EA-1047C4A9F330
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pathogenesis of thrombotic microangiopathies
@ast
Pathogenesis of thrombotic microangiopathies
@en
Pathogenesis of thrombotic microangiopathies
@nl
type
label
Pathogenesis of thrombotic microangiopathies
@ast
Pathogenesis of thrombotic microangiopathies
@en
Pathogenesis of thrombotic microangiopathies
@nl
prefLabel
Pathogenesis of thrombotic microangiopathies
@ast
Pathogenesis of thrombotic microangiopathies
@en
Pathogenesis of thrombotic microangiopathies
@nl
P2860
P1476
Pathogenesis of thrombotic microangiopathies
@en
P2093
X Long Zheng
P2860
P304
P356
10.1146/ANNUREV.PATHMECHDIS.3.121806.154311
P407
P577
2008-01-01T00:00:00Z